NBY  Novabay Pharmaceuticals Inc.

Exchange

AMEX

Sector

Consumer Durables

Industry

Major Pharmaceuticals

Market Cap.

48.6M

Vuru Grade

30.66/100

Current Price

$0.96
+0.0182 (+1.94%)

Growth Price

$0.05
Overvalued by 95.30%

Company Metrics

  • 0 P/E
  • 17.38 P/S
  • 4.03 P/B
  • -0.387 EPS
  • -2,638.06% Cash ROIC
  • 4.98 Cash Ratio
  • 0.00 / N/A % Dividend
  • 200,668.00 Avg. Vol.
  • 25.77M Shares
  • 48.6M Market Cap.

Company Description

NovaBay Pharmaceuticals Inc., a clinical stage biotechnology company, engages in developing proprietary and patented topical Aganocide compounds for the treatment and prevention of various infections without causing bacterial resistance. Its Aganocide compounds are synthetic anti-infective product candidates with equivalent activity to the active antimicrobial molecules generated within white bloo...
more


Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow

News

NovaBay Pharmaceuticals Announces Direct US Marketing-Sales Campaign for ...
Business Wire (press release) - Jul 16, 2014
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay Pharmaceuticals, Inc. (NYSE MKT:NBY), a biopharmaceutical company focusing on the development and commercialization of its non-antibiotic anti-infectives, announced today it will initiate a major ...
NovaBay's New Product for Serious Eye Conditions Highlighted in CEOLIVE.TV ...
Wall Street Journal - Jul 3, 2014
NovaBay(R) Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company focusing on non-antibiotic anti-infectives, announced today that CEOLIVE.
Investors Alert – GoPro Inc (NASDAQ:GPRO), Con-way Inc (NYSE:CNW ...
Crazy Joys - Jul 13, 2014
On 3 JULY NovaBay Pharmaceuticals, Inc. (NYSEMKT:NBY) announced that CEOLIVE.TV, an online service that delivers news about companies to investors, has highlighted NovaBay's important advance in eye care throughan interview with Kathryn ...
Dr. Christine W. Sindt Will Describe Benefits of NovaBay's i-Lid Cleanser at ...
MarketWatch - Jun 26, 2014
EMERYVILLE, Calif., Jun 26, 2014 (BUSINESS WIRE) -- NovaBay® Pharmaceuticals, Inc. (nyse mkt:NBY), a clinical-stage biopharmaceutical company, announced today that Christine Sindt OD, Clinical Associate Professor of Ophthalmology and Visual ...
Bullish runners – Transportadora de Gas Del Sur S.A. (TGS), NovaBay ...
Techsonian (press release) - Jul 21, 2014
Transportadora de Gas del Sur SA (ADR) (NYSE:TGS) works as a gas transportation company in Latin America. TGS transports and supplies natural gas to distribution companies, industries, traders, producers, and power plant operators, as well as 4.6 ...
British Prime Minister David Cameron Warns of Growing Crisis of Antibiotic ...
Wall Street Journal - Jul 2, 2014
Dr. Crew's innovation was irrigating the spreading wounds of necrotizing fasciitis victims with NeutroPhase, a product from NovaBay(R) Pharmaceuticals, Inc. (NYSE MKT: NBY), a California based biopharmaceutical company. NeutroPhase contains a pure ...
Letter to NovaBay Shareholders
Wall Street Journal - Jul 10, 2014
NovaBay(R) Pharmaceuticals, Inc. (NYSE MKT:NBY), a biopharmaceutical company focusing on non-antibiotic anti-infectives, announced today the distribution of a letter from Ron Najafi, the Company's Chairman, Chief Executive Officer, to its stockholders.
Neurotrope Board of Directors Appoints Chairmen Ramat and Freiman as ...
Wall Street Journal - Jul 18, 2014
He serves as Chairman of Chronix BioMedical and is a member of the NovaBay Pharmaceutical Board of Directors. In the past, Mr. Freiman served on the Boards of Otsuka America, Inc. and several biotechnology companies based in the United States and ...
NovaBay Pharmaceuticals Inc prices public offering
Reuters Key Development - Mar 20, 2014